Key Points Hims & Hers Health is entering the Canadian market.The company will offer a generic version of semaglutide in the ...

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper ...

In an echo of the pattern laid last year, following a record-high outlay at the very beginning of the year, TV drug ad ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

Novo Nordisk just pulled Wegovy from a major telehealth platform over safety concerns about knockoff versions. Here's what millions of weight-loss drug users need to know before their next ...

Find insight on Novo Nordisk, European drug exports, and more in the latest Market Talks covering Health Care.

While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

NEW YORK >> More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Hims & Hers (HIMS) stock in focus as the company faces a growing number of lawsuits following Novo Nordisk's (NVO) decision ...